Indegene has authorized the execution of a definitive settlement agreement to resolve a class-action lawsuit involving its wholly-owned overseas subsidiary, Indegene, Inc. The company confirmed on August 19, 2026, that it has no further comments on the agreement following final clarifications from external counsel on August 18, 2026. The settlement remains subject to execution by relevant parties and approval by the U.S. District Court, District of New Jersey.

Settlement structure and financial impact

The lawsuit, Progressive Health and Rehab Corp. v. Indegene, Inc. et al., concerns alleged violations of the U.S. Telephone Consumer Protection Act, 1991 (TCPA) related to certain fax communications executed in February 2020. In July 2025, the court certified a class comprising approximately 18,851 unique fax numbers, representing 18,869 transmissions. The defendants' petition seeking permission to appeal this certification was denied, leading to mediation and subsequent negotiations.

The agreed settlement framework establishes a maximum settlement fund of approximately USD 4.72 million. This figure is derived from a payment of USD 250 per eligible approved claim. Crucially, the settlement is structured on a claims-made and reversionary basis. Indegene is not required to deposit or pre-fund the entire maximum amount upfront. Instead, actual payments will depend on the number of valid and approved claims submitted by class members. Any amounts not required to satisfy approved claims, along with other payments contemplated under the settlement, will revert to the defendants.

Administrative costs and next steps

The settlement does not constitute an admission of liability by Indegene or its subsidiary. The parties have identified Analytics as the settlement administrator, with estimated administration costs of approximately USD 42,559. The notice mechanics contemplate an initial fax notice, with fallback to U.S. First Class Mail where unsuccessful.

The next steps involve filing the settlement documentation with the court, obtaining preliminary approval, issuing class notices, and conducting claims administration. Final court approval is required before any payments are made to class members. The company will assess the accounting impact in accordance with applicable accounting standards once the process concludes.

What the Numbers Show

The reversionary nature of the settlement significantly mitigates the potential cash outflow for Indegene. While the maximum exposure is capped at USD 4.72 million, the actual financial impact will likely be lower, depending on the participation rate of the certified class. With an estimated administrative cost of only USD 42,559, the overhead for resolving this long-pending litigation is minimal relative to the maximum fund size. The absence of upfront funding requirements preserves liquidity, allowing the company to manage cash flows based on actual approved claims rather than a worst-case scenario.

Shareholders of Indegene passed all five resolutions proposed at its 28th Annual General Meeting (AGM) held on August 13, 2026. The meeting, conducted via video conferencing and other audio-visual means, covered routine business including the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the declaration of a final dividend. The most significant governance change was the appointment of Ms. Jill Mary De Simone as an independent director through a special resolution, which received 91.96% support from votes polled.

The AGM transcript provided detailed insights into the company’s financial performance and strategic direction for FY26. Revenue grew 23.6% to ₹35,105 crore (USD396.9 million), crossing the ₹3,500 crore annual threshold for the first time. EBITDA grew 11.1% to ₹6,247 crore, while profit after tax (PAT) stood at ₹4,011 crore. Management noted that margins deliberately absorbed heavy investments in AI consulting and delivery, alongside the integration of its largest acquisition, BioPharm.

Financial Performance and Segment Growth

The company reorganized into two major segments during FY26. Enterprise Commercial Solutions grew approximately 27.0% to ₹2,461 crore, while Enterprise Medical Solutions grew about 16.0% to ₹930 crore. The company generated roughly ₹650 crore of operating cash and remains debt-free with bank balances and current investments of ₹1,481 crore. A final dividend of ₹2.25 per share was recommended, an increase from ₹2.00 in the previous year, supported by strong free cash flow which grew 162% year-on-year.

Strategic Acquisitions and Client Base

Indegene completed three strategic acquisitions in FY26 to strengthen capabilities and deepen geographic presence. The largest was BioPharm, acquired in October 2025 for approximately ₹882 crore (USD104 million), adding advanced AI and digital advertising capabilities. Two other acquisitions, Warn & Company and Cake Kommunikations, brought expertise in key European markets. All three are now fully integrated.

The client base expanded significantly, with active clients growing from 73 to 91. Clients generating more than USD1 million in revenue increased from 41 to 53. The top five customers constitute about 30% of total revenues, a figure that has consistently reduced as the customer base broadened from 50 to over 100 clients in the last five years. The largest single customer accounts for just under 10% of revenue.

AI Integration and Margin Outlook

Management emphasized that Indegene is not merely adopting AI but redesigning operating models around it. The company has developed a life sciences native technology stack called Cortex, a proprietary LLM-agnostic reasoning engine. Key AI-driven solutions include One-Click Submissions, Agentic AOR, and Human-less MLR. These tools have already processed over 65,000 medico-legal review assets in 2025.

Regarding margins, CFO Suhas Prabhu explained that EBITDA margins were depressed due to front-end leadership investments and a large outcome-based deal signed in December 2025. He projected that these factors would normalize by Q4FY27, allowing EBITDA margins to return to the historical range of 19% to 20%. PAT margins will continue to be impacted by higher amortization charges from acquisitions, which are expected to decline by approximately ₹50 crore per quarter starting Q3FY27.

Voting Participation and Results

Total voting rights were reckoned as on August 7, 2026. The company reported a total of 136,695 shareholders on the record date. Approximately 79.8% of outstanding shares were voted across the resolutions. Institutional investors held 64,957,781 shares, while public non-institutional shareholders held 175,996,524 shares.

Scrutinizer Report Details

Madhwesh K, a practicing company secretary, served as the scrutinizer for the voting process. The report noted that votes cast by 13 corporate shareholders were deemed invalid due to non-receipt of requisite board resolutions or proper authorization as mandated by the Companies Act, 2013. These invalid votes totaled 3,904,235 shares across all resolutions.

What the Numbers Show

The voting data reveals a distinct divergence in shareholder sentiment regarding the appointment of Dr. Sanjay Suresh Parikh compared to other board members. While institutional investors supported Mr. Gupta’s appointment with 98.94% approval, they backed Dr. Parikh with only 91.80% approval, casting over 4.5 million votes against his reappointment. In contrast, public non-institutional shareholders supported both directors with near-unanimous approval (99.99% and 99.99% respectively). This suggests specific institutional concerns or preferences regarding Dr. Parikh’s tenure, despite the overall passage of the resolution.